JANUX THERAPEUTICS INC JANX
COM · Common Stock · CUSIP 47103J105
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersSan Diego, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 41.6m as of 2021-08-06, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $24.83.
Biggest buyers
| RA CAPITAL MANAGEMENT, L.P. | New | +8.7m |
| ORBIMED ADVISORS LLC | New | +3.5m |
| JANUS HENDERSON GROUP PLC | New | +2.7m |
| CITADEL ADVISORS LLC | New | +1.9m |
| FMR LLC | New | +1.8m |
| EcoR1 Capital, LLC | New | +1.4m |
| BVF INC/IL | New | +1.2m |
| DEERFIELD MANAGEMENT COMPANY, L.P. | New | +700.0k |
| SAMSARA BIOCAPITAL, LLC | New | +607.9k |
| Logos Global Management LP | New | +547.1k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. 13D · may seek influence filed 2025-03-10 | 19.9% |
| BlackRock, Inc. 13G · institution +1.0 pts · filed 2026-07-28 | 6.7% |
| Prosight Management, LP 13G · passive investor new · filed 2026-02-06 | 5.3% |
Fell to 5% or below in the last year: Point72 Asset Management, L.P. (3.3%, 2026-08-14), Janus Henderson Group Ltd. (0.3%, 2026-08-13), STATE STREET CORP (4.1%, 2026-05-12), FMR LLC (4.2%, 2026-05-06)
Insider purchases and sales in Q2 2021
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2019 | 0 | — | 0 | — | — |
| Q4 2019 | 0 | — | 0 | — | — |
| Q1 2020 | 0 | — | 0 | — | — |
| Q2 2020 | 0 | — | 0 | — | — |
| Q3 2020 | 0 | — | 0 | — | — |
| Q4 2020 | 0 | — | 0 | — | — |
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 5 | $72.7m | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2021-06-15 | RA Capital Healthcare Fund LP +3 Director · See footnotes | Bought | $50.0m2.9m shares |
| 2021-06-15 | ORBIMED ADVISORS LLC +2 Director · See footnotes | Bought | $12.0m705.9k shares |
| 2021-06-15 | Thompson Peter A. Director · See footnotes | Bought | $12.0m705.9k shares |
| 2021-06-15 | Reardon Tighe Acting Chief Financial Officer · See footnote | Bought | $10.7m629.4k shares |
| 2021-06-15 | Avalon Ventures XI, L.P. +1 10% owner | Bought | $10.7m629.4k shares |
| 2021-06-15 | Lichter Jay Director · See footnote | Bought | $10.7m629.4k shares |
| 2021-06-15 | Bregua Corp 10% owner | Bought | $1,000.0k58.8k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2021
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. 3.47% of their portfolio | 8.7m $216.3m | New |
| ORBIMED ADVISORS LLC 0.88% of their portfolio | 3.5m $86.5m | New |
| JANUS HENDERSON GROUP PLC 0.03% of their portfolio | 2.7m $64.5m | New |
| CITADEL ADVISORS LLC 0.05% of their portfolio | 1.9m $46.2m | New |
| FMR LLC 0.00% of their portfolio | 1.8m $46.0m | New |
| EcoR1 Capital, LLC 1.32% of their portfolio | 1.4m $35.2m | New |
| BVF INC/IL 1.10% of their portfolio | 1.2m $29.4m | New |
| DEERFIELD MANAGEMENT COMPANY, L.P. 0.31% of their portfolio | 700.0k $17.5m | New |
| SAMSARA BIOCAPITAL, LLC 1.99% of their portfolio | 607.9k $15.2m | New |
| Logos Global Management LP 1.17% of their portfolio | 547.1k $13.7m | New |
| ADAGE CAPITAL PARTNERS GP, L.L.C. 0.02% of their portfolio | 450.0k $11.2m | New |
| 5AM Venture Management, LLC 2.80% of their portfolio | 446.3k $11.1m | New |
| Woodline Partners LP 0.16% of their portfolio | 334.3k $8.3m | New |
| BlackRock Inc. 0.00% of their portfolio | 109.9k $2.7m | New |
| CITIGROUP INC 0.00% of their portfolio | 86.7k $2.2m | New |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 75.3k $1.9m | New |
| GOLDMAN SACHS GROUP INC 0.00% of their portfolio | 69.0k $1.7m | New |
| LMR Partners LLP 0.02% of their portfolio | 57.0k $1.4m | New |
| Pinz Capital Management, LP 0.24% of their portfolio | 32.1k $801.0k | New |
| VANGUARD GROUP INC 0.00% of their portfolio | 29.0k $723.0k | New |
| ExodusPoint Capital Management, LP 0.01% of their portfolio | 24.6k $613.0k | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 22.0k $549.0k | New |
| Qube Research & Technologies Ltd 0.00% of their portfolio | 14.3k $357.0k | New |
| WELLINGTON MANAGEMENT GROUP LLP 0.00% of their portfolio | 9.2k $229.0k | New |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 2.0k $52.0k | New |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 1.3k $32.0k | New |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 646 $16.0k | New |
| UBS Group AG 0.00% of their portfolio | 353 $9.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 100 $2.0k | New |
| US BANCORP \DE\ 0.00% of their portfolio | 7 $0 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |